|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Kim J, Harper A, McCormack V, Sung H,
Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I and
Fidler-Benaoudia MM: Global patterns and trends in breast cancer
incidence and mortality across 185 countries. Nat Med.
31:1154–1162. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gradishar WJ, Moran MS, Abraham J,
Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J,
Burstein HJ, et al: Breast cancer, version 3.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
22:331–357. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pourhanifeh MH, Farrokhi-Kebria H,
Mostanadi P, Farkhondeh T and Samarghandian S: Anticancer
properties of baicalin against breast cancer and other
gynecological cancers: Therapeutic opportunities based on
underlying mechanisms. Curr Mol Pharmacol. 17:e187614292630632024.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hussain MS, Agrawal M, Shaikh NK, Saraswat
N, Bahl G, Maqbool Bhat M, Khurana N, Bisht AS, Tufail M and Kumar
R: Beyond the genome: Deciphering the role of MALAT1 in breast
cancer progression. Curr Genomics. 25:343–357. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lumachi F, Luisetto G, Basso SM, Basso U,
Brunello A and Camozzi V: Endocrine therapy of breast cancer. Curr
Med Chem. 18:513–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Araghi M, Gharebakhshi F, Faramarzi F,
Mafi A, Mousavi T, Alimohammadi M and Soleimantabar H: Efficacy and
safety of pembrolizumab monotherapy or combined therapy in patients
with metastatic Triple-negative breast cancer: A Systematic review
and Meta-analysis of randomized controlled trials. Curr Gene Ther.
25:72–88. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnston SJ and Cheung KL: Endocrine
therapy for breast cancer: A model of hormonal manipulation. Oncol
Ther. 6:141–156. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members, : Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Torun V, Degerli E and Cansaran-Duman D:
Revealing the molecular signatures of miR-185-5p on breast cancer
cells using proteomic analysis. Protein Pept Lett. 31:681–695.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Early Breast Cancer Trialists' and
Collaborative Group (EBCTCG), . Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance
of breast cancer hormone receptors and other factors to the
efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Howell A, Cuzick J, Baum M, Buzdar A,
Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and
Tobias JS; ATAC Trialists' Group, : Results of the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial after completion of 5
years' adjuvant treatment for breast cancer. Lancet. 365:60–62.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bidard FC, Kaklamani VG, Neven P, Streich
G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D,
Harnden KK, et al: Elacestrant (oral selective estrogen receptor
degrader) versus standard endocrine therapy for estrogen
receptor-positive, human epidermal growth factor receptor
2-negative advanced breast cancer: Results from the randomized
phase III EMERALD trial. J Clin Oncol. 40:3246–3256. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johnston SRD, Toi M, O'Shaughnessy J,
Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG,
Cicin I, et al: Abemaciclib plus endocrine therapy for hormone
receptor-positive, HER2-negative, node-positive, high-risk early
breast cancer (monarchE): Results from a preplanned interim
analysis of a randomised, open-label, phase 3 trial. Lancet Oncol.
24:77–90. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayer EL, Dueck AC, Martin M, Rubovszky G,
Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP,
Pfeiler G, et al: Palbociclib with adjuvant endocrine therapy in
early breast cancer (PALLAS): Interim Analysis of a multicentre,
open-label, randomised, phase 3 study. Lancet Oncol. 22:212–222.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bardia ABF, Neven P, Streich G, Montero
AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK,
Khong H, et al: Abstract GS3-01: GS3-01 EMERALD phase 3 trial of
elacestrant versus standard of care endocrine therapy in patients
with ER+/HER2-metastatic breast cancer: Updated results by duration
of prior CDK4/6i in metastatic setting. Cancer Res. 83 (Suppl
5):GS3–01. 2023. View Article : Google Scholar
|
|
18
|
Moore GR and Labatut AE: Updates in
endocrine-resistant metastatic breast cancer and Treatment-related
adverse event management. Curr Breast Cancer Rep. 17:532025.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rugo HS, Kaklamani V, Mcarthur H, Wander
SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E,
Maitland J, et al: Real-world outcomes of elacestrant in ER+,
HER2-, ESR1-mutant metastatic breast cancer. Clin Cancer Res.
32:179–187. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swallow E, Maitland J, Sarathy K, Sears E,
Nagarwala Y, Depalantino J, Kruep E, Pelletier C, Kloss S and
Wasserman T: Elacestrant real-world progression-free survival
(rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A
retrospective analysis using insurance claims in the United States.
Clin Cancer Res. 31:31008. 2025. View Article : Google Scholar
|
|
21
|
Neven P, Fasching PA, Chia S, Jerusalem G,
De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A,
et al: Updated overall survival from the MONALEESA-3 trial in
postmenopausal women with HR+/HER2-advanced breast cancer receiving
first-line ribociclib plus fulvestrant. Breast Cancer Res.
25:1032023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
The effect of abemaciclib plus fulvestrant on overall survival in
hormone Receptor-Positive, ERBB2-Negative breast cancer that
progressed on endocrine Therapy-MONARCH 2: A randomized clinical
trial. JAMA Oncol. 6:116–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robertson JFR, Shao Z, Noguchi S,
Bondarenko I, Panasci L, Singh S, Subramaniam S and Ellis MJ:
Fulvestrant versus anastrozole in endocrine Therapy-naïve women
with hormone receptor-Positive advanced breast cancer: Final
overall survival in the phase III FALCON trial. J Clin Oncol.
43:1539–1545. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cristofanilli M, Rugo HS, Im SA, Slamon
DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi
S, et al: Overall survival with palbociclib and fulvestrant in
women with HR+/HER2-ABC: Updated exploratory analyses of PALOMA-3,
a Double-blind, Phase III randomized study. Clin Cancer Res.
28:3433–3442. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slamon D, Lipatov O, Nowecki Z, McAndrew
N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS,
Fasching PA, Crown J, et al: Ribociclib plus endocrine therapy in
early breast cancer. N Engl J Med. 390:1080–1091. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe
JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, et al: Effect of
palbociclib plus endocrine therapy on time to chemotherapy across
subgroups of patients with hormone receptor-positive/human
epidermal growth factor receptor 2-negative advanced breast cancer:
Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 66:324–331.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bardia A, Hurvitz SA, DeMichele A, Clark
AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, et
al: Phase I/II trial of exemestane, ribociclib, and everolimus in
women with HR+/HER2-Advanced breast cancer after progression on
CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 27:4177–4185. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C,
DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, et al:
PACE: A randomized phase II study of fulvestrant, palbociclib, and
avelumab after progression on Cyclin-Dependent kinase 4/6 inhibitor
and aromatase inhibitor for hormone Receptor-Positive/Human
epidermal growth factor Receptor-negative metastatic breast cancer.
J Clin Oncol. 42:2050–2060. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shah M, Osgood CL, Amatya AK, Fiero MH,
Pierce WF, Nair A, Herz J, Robertson KJ, Mixter BD, Tang S, et al:
FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant
treatment of patients with High-risk early-stage triple-negative
breast cancer. Clin Cancer Res. 28:5249–5253. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmid P, Oliveira M, O'Shaughnessy J,
Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW,
et al: TROPION-Breast05: A randomized phase III study of Dato-DXd
with or without durvalumab versus chemotherapy plus pembrolizumab
in patients with PD-L1-high locally recurrent inoperable or
metastatic triple-negative breast cancer. Ther Adv Med Oncol.
17:175883592513279922025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Im SA, Cortes J, Cescon DW, Yusof MM,
Iwata H, Masuda N, Takano T, Huang CS, Chung CF, Tsugawa K, et al:
Results from the randomized KEYNOTE-355 study of pembrolizumab plus
chemotherapy for Asian patients with advanced TNBC. NPJ Breast
Cancer. 10:792024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof
MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, et
al: Pembrolizumab plus chemotherapy in advanced Triple-negative
breast cancer. N Engl J Med. 387:217–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burstein HJ, Somerfield MR, Barton DL,
Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton
JK, Macrae ER, et al: Endocrine treatment and targeted therapy for
hormone Receptor-Positive, human epidermal growth factor receptor
2-Negative metastatic breast cancer: ASCO guideline update. J Clin
Oncol. 39:3959–3977. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Di Grazia G, Dri A, Grieco A, Martinelli
C, Palleschi M, Martorana F, Barchiesi G, Arpino G, De Angelis C,
De Laurentiis M, et al: Unlocking the potential of immune
checkpoint inhibitors in HR+/HER2-breast cancer: A systematic
review. Cancers (Basel). 17:29402025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heater NK, Warrior S and Lu J: Current and
future immunotherapy for breast cancer. J Hematol Oncol.
17:1312024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jerusalem G, Prat A, Salgado R, Reinisch
M, Saura C, Ruiz-Borrego M, Nikolinakos P, Ades F, Filian J, Huang
N, et al: Neoadjuvant nivolumab + palbociclib + anastrozole for
oestrogen receptor-positive/human epidermal growth factor receptor
2-negative primary breast cancer: Results from CheckMate 7A8.
Breast. 72:1035802023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rugo HS, Delord JP, Im SA, Ott PA,
Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen
EMJ, Varga A, et al: Safety and antitumor activity of pembrolizumab
in patients with estrogen Receptor-Positive/Human epidermal growth
factor receptor 2-Negative advanced breast cancer. Clin Cancer Res.
24:2804–2811. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dirix LY, Takacs I, Jerusalem G,
Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME,
Somer R, Smakal M, et al: Avelumab, an anti-PD-L1 antibody, in
patients with locally advanced or metastatic breast cancer: A phase
1b JAVELIN Solid tumor study. Breast Cancer Res Treat. 167:671–686.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and Nab-Paclitaxel in advanced Triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rugo HS, Loi S, Adams S, Schmid P,
Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM,
et al: PD-L1 immunohistochemistry assay comparison in atezolizumab
plus nab-Paclitaxel-Treated advanced Triple-negative breast cancer.
J Natl Cancer Inst. 113:1733–1743. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spranger S and Gajewski TF: Impact of
oncogenic pathways on evasion of antitumour immune responses. Nat
Rev Cancer. 18:139–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brufsky AM and Dickler MN: Estrogen
Receptor-positive breast cancer: Exploiting signaling pathways
implicated in endocrine resistance. Oncologist. 23:528–539. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hanker AB, Sudhan DR and Arteaga CL:
Overcoming endocrine resistance in breast cancer. Cancer Cell.
37:496–513. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Belachew EB and Sewasew DT: Molecular
mechanisms of endocrine resistance in Estrogen-positive breast
cancer. Front Endocrinol (Lausanne). 12:5995862021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jeselsohn R, Buchwalter G, De Angelis C,
Brown M and Schiff R: ESR1 mutations-a mechanism for acquired
endocrine resistance in breast cancer. Nat Rev Clin Oncol.
12:573–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fribbens C, O'Leary B, Kilburn L, Hrebien
S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S,
Loibl S, et al: Plasma ESR1 mutations and the treatment of estrogen
Receptor-positive advanced breast cancer. J Clin Oncol.
34:2961–2968. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wagner J, Rapsomaniki MA, Chevrier S,
Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst
S, Soysal SD, et al: A Single-cell atlas of the tumor and immune
ecosystem of human breast cancer. Cell. 177:1330–1345.e18. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ye J, Baer JM, Faget DV, Morikis VA, Ren
Q, Melam A, Delgado AP, Luo X, Bagchi SM, Belle JI, et al:
Senescent CAFs mediate immunosuppression and drive breast cancer
progression. Cancer Discov. 14:1302–1323. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chandarlapaty S, Chen D, He W, Sung P,
Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, et al:
Prevalence of ESR1 mutations in cell-free DNA and outcomes in
metastatic breast cancer: A secondary analysis of the BOLERO-2
clinical trial. JAMA Oncol. 2:1310–1315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Magnani L, Frige G, Gadaleta RM, Corleone
G, Fabris S, Kempe MH, Verschure PJ, Barozzi I, Vircillo V, Hong
SP, et al: Acquired CYP19A1 amplification is an early specific
mechanism of aromatase inhibitor resistance in ERα metastatic
breast cancer. Nat Genet. 49:444–4450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pagani O, Regan MM, Walley BA, Fleming GF,
Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, et
al: Adjuvant exemestane with ovarian suppression in premenopausal
breast cancer. N Engl J Med. 371:107–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Francis PA, Pagani O, Fleming GF, Walley
BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein
HJ, et al: Tailoring adjuvant endocrine therapy for premenopausal
breast cancer. N Engl J Med. 379:122–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bellet M, Gray KP, Francis PA, Láng I,
Ciruelos E, Lluch A, Climent MA, Catalán G, Avella A, Bohn U, et
al: Twelve-Month estrogen levels in premenopausal women with
hormone Receptor-Positive breast cancer receiving adjuvant
triptorelin plus exemestane or tamoxifen in the suppression of
ovarian function trial (SOFT): The SOFT-EST substudy. J Clin Oncol.
34:1584–1593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tripathy D, Im S, Colleoni M, Franke F,
Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, et al:
Ribociclib plus endocrine therapy for premenopausal women with
hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A
randomised phase 3 trial. Lancet Oncol. 19:904–915. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lung Cancer Specialty Committee of Chinese
Elderly Health Care Association, Lung Cancer Specialty Committee of
Beijing Cancer Society, . Consensus of Chinese experts on medical
treatment of advanced lung cancer in the elderly (2022 edition).
Chin J Lung Cancer. 25:363–384. 2022.(In Chinese).
|
|
61
|
Breast Committee of Chinese Research
Hospital Association and Geriatric Oncology Sub-Committee of
Chinese Geriatric Society, Consensus Expert Group on Diagnosis,
Treatment of Elderly Breast Cancer in China, . Consensus on the
diagnosis and treatment of breast carcinoma in elderly Chinese
patients (2023 edition). Chin Res Hosp. 10:1–8. 2023.(In
Chinese).
|
|
62
|
Harbeck N, Brufsky A, Grace Rose C,
Korytowsky B, Chen C, Tantakoun K, Jazexhi E, Nguyen DHV, Bartlett
M, Samjoo IA and Pluard T: Real-world effectiveness and safety of
CDK4/6i in elderly and BIPOC patients with
HR+/HER2-advanced/metastatic breast cancer: An updated systematic
literature review. Front Oncol. 15:15770752025. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jenkins S, Kachur ME, Rechache K, Wells JM
and Lipkowitz S: Rare breast cancer subtypes. Curr Oncol Rep.
23:542021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Petrausch U and Pestalozzi BC: Distinct
clinical and prognostic features of invasive lobular breast cancer.
Breast Dis. 30:39–44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Berx G and Van Roy F: The
E-cadherin/catenin complex: An important gatekeeper in breast
cancer tumorigenesis and malignant progression. Breast Cancer Res.
3:289–293. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: Comprehensive molecular portraits of invasive lobular breast
cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Borst MJ and Ingold JA: Metastatic
patterns of invasive lobular versus invasive ductal carcinoma of
the breast. Surgery. 114:637–641. 1993.PubMed/NCBI
|
|
69
|
Metzger Filho O, Giobbie-Hurder A, Mallon
E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD,
Colleoni M, Ejlertsen B, et al: Relative effectiveness of letrozole
compared with tamoxifen for patients with lobular carcinoma in the
BIG 1–98 trial. J Clin Oncol. 33:2772–2779. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Early Breast Cancer Trialists' and
Collaborative Group (EBCTCG), . Aromatase inhibitors versus
tamoxifen in early breast cancer: Patient-level meta-analysis of
the randomised trials. Lancet. 386:1341–1352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kumegawa K, Takahashi Y, Saeki S, Yang L,
Nakadai T, Osako T, Mori S, Noda T, Ohno S, Ueno T and Maruyama R:
GRHL2 motif is associated with intratumor heterogeneity of
cis-regulatory elements in luminal breast cancer. NPJ Breast
Cancer. 8:702022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fang K, Ohihoin AG, Liu T, Choppavarapu L,
Nosirov B, Wang Q, Yu XZ, Kamaraju S, Leone G and Jin VX:
Integrated single-cell analysis reveals distinct
epigenetic-regulated cancer cell states and a heterogeneity-guided
core signature in Tamoxifen-resistant breast cancer. Genome Med.
16:1342024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Nolan E, Lindeman GJ and Visvader JE:
Deciphering breast cancer: From biology to the clinic. Cell.
186:1708–1728. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Azizi E, Carr AJ, Plitas G, Cornish AE,
Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M,
et al: Single-Cell map of diverse immune phenotypes in the breast
tumor microenvironment. Cell. 174:1293–1308.e36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu SZ, Al-Eryani G, Roden DL, Junankar S,
Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N,
et al: A single-cell and spatially resolved atlas of human breast
cancers. Nat Genet. 53:1334–1347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Liu YM, Ge JY, Chen YF, Liu T, Chen L, Liu
CC, Ma D, Chen YY, Cai YW, Xu YY, et al: Combined Single-Cell and
spatial transcriptomics reveal the metabolic evolvement of breast
cancer during early dissemination. Adv Sci (Weinh).
10:e22053952023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Spoerke JM, Gendreau S, Walter K, Qiu J,
Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, et al:
Heterogeneity and clinical significance of ESR1 mutations in
ER-positive metastatic breast cancer patients receiving
fulvestrant. Nat Commun. 7:115792016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang P, Bahreini A, Gyanchandani R, Lucas
PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE,
Berg A, Hamilton RL, et al: Sensitive detection of Mono- and
polyclonal ESR1 mutations in primary tumors, metastatic lesions,
and cell-free DNA of breast cancer patients. Clin Cancer Res.
22:1130–1137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Dahlgren M, George AM, Brueffer C,
Gladchuk S, Chen Y, Vallon-Christersson J, Hegardt C, Häkkinen J,
Rydén L, Malmberg M, et al: Preexisting somatic mutations of
estrogen receptor alpha (ESR1) in Early-Stage primary breast
cancer. JNCI Cancer Spectr. 5:pkab0282021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim H, Whitman AA, Wisniewska K, Kakati
RT, Garcia-Recio S, Calhoun BC, Franco HL, Perou CM and Spanheimer
PM: Tamoxifen response at Single-cell resolution in estrogen
receptor-positive primary human breast tumors. Clin Cancer Res.
29:4894–4907. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Dini A, Barker H, Piki E, Sharma S,
Raivola J, Murumägi A and Ungureanu D: A multiplex single-cell
RNA-Seq pharmacotranscriptomics pipeline for drug discovery. Nat
Chem Biol. 21:432–442. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yuan J, Yang L, Li Z, Zhang H, Wang Q,
Huang J, Wang B, Mohan CD, Sethi G and Wang G: The role of the
tumor microenvironment in endocrine therapy resistance in hormone
receptor-positive breast cancer. Front Endocrinol (Lausanne).
14:12612832023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Bartoschek M, Oskolkov N, Bocci M, Lövrot
J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson
G, et al: Spatially and functionally distinct subclasses of breast
cancer-associated fibroblasts revealed by single cell RNA
sequencing. Nat Commun. 9:51502018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Fribbens C, Garcia Murillas I, Beaney M,
Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E,
Rosenfeld N, et al: Tracking evolution of aromatase inhibitor
resistance with circulating tumour DNA analysis in metastatic
breast cancer. Ann Oncol. 29:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Caldwell BA, Wu Y, Wang J and Li L:
Altered DNA methylation underlies monocyte dysregulation and immune
exhaustion memory in sepsis. Cell Rep. 43:1138942024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Xiong S, Song K, Xiang H and Luo G:
Dual-target inhibitors based on ERα: Novel therapeutic approaches
for endocrine resistant breast cancer. Eur J Med Chem.
270:1163932024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Svensson V, da Veiga Beltrame E and
Pachter L: A curated database reveals trends in Single-cell
transcriptomics. Nat Methods. 17:795–799. 2020.
|
|
89
|
Luecken MD and Theis FJ: Current best
practices in single-cell RNA-seq analysis: A tutorial. Mol Syst
Biol. 15:e87462019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Regev A, Teichmann SA, Lander ES, Amit I,
Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P,
Clatworthy M, et al: The human cell atlas. Elife. 6:e270412017.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Stuart T, Butler A, Hoffman P, Hafemeister
C, Papalexi E, Mauck WM III, Hao Y, Stoeckius M, Smibert P and
Satija R: Comprehensive integration of single-cell data. Cell.
177:1888–1902.e21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tran HTN, Ang KS, Chevrier M, Zhang X, Lee
NYS, Goh M and Chen J: A benchmark of batch-effect correction
methods for single-cell RNA-seq data. Genome Biol. 21:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kiselev VY, Andrews TS and Hemberg M:
Challenges in unsupervised clustering of single-cell RNA-seq data.
Nat Rev Genet. 20:273–282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Hicks SC, Townes FW, Teng M and Irizarry
RA: Missing data and technical variability in single-cell
RNA-sequencing experiments. Biostatistics. 19:562–578. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Sachs N and Clevers H: Organoid cultures
for the analysis of cancer phenotypes. Curr Opin Genet Dev.
24:68–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Dhimolea E, de Matos Simoes R, Kansara D,
Weng X, Sharma S, Awate P, Liu Z, Gao D, Mitsiades N, Schwab JH, et
al: Pleiotropic mechanisms drive endocrine resistance in the
Three-dimensional bone microenvironment. Cancer Res. 81:371–383.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Rosenbluth JM, Schackmann RCJ, Gray GK,
Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J,
Garber J, et al: Organoid cultures from normal and cancer-prone
human breast tissues preserve complex epithelial lineages. Nat
Commun. 11:17112020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wu H, Wang W, Zhang Y, Chen Y, Shan C, Li
J, Jia Y, Li C, Du C, Cai Y, et al: Establishment of
patient-derived organoids for guiding personalized therapies in
breast cancer patients. Int J Cancer. 155:324–338. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vlachogiannis G, Hedayat S, Vatsiou A,
Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford
I, Burke R, et al: Patient-derived organoids model treatment
response of metastatic gastrointestinal cancers. Science.
359:920–926. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pan B, Li X, Zhao D, Li N, Wang K, Li M
and Zhao Z: Optimizing individualized treatment strategy based on
breast cancer organoid model. Clin Transl Med. 11:e3802021.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Chen P, Zhang X, Ding R, Yang L, Lyu X,
Zeng J, Lei JH, Wang L, Bi J, Shao N, et al: Patient-Derived
organoids can guide Personalized-therapies for patients with
advanced breast cancer. Adv Sci (Weinh). 8:e21011762021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bruna A, Rueda OM, Greenwood W, Batra AS,
Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW,
Tufegdzic-Vidakovic A, et al: A biobank of breast cancer explants
with preserved Intra-tumor heterogeneity to screen anticancer
compounds. Cell. 167:260–274.e22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ma S, Tang T, Probst G, Konradi A, Jin C,
Li F, Gutkind JS, Fu XD and Guan KL: Transcriptional repression of
estrogen receptor alpha by YAP reveals the Hippo pathway as
therapeutic target for ER+ breast cancer. Nat Commun. 13:10612022.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Guillen KP, Fujita M, Butterfield AJ,
Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E,
Yang CH, et al: A human breast cancer-derived xenograft and
organoid platform for drug discovery and precision oncology. Nat
Cancer. 3:232–250. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Önder CE, Ziegler TJ, Becker R, Brucker
SY, Hartkopf AD, Engler T and Koch A: Advancing cancer therapy
predictions with Patient-derived organoid models of metastatic
breast cancer. Cancers (Basel). 15:36022023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Guan D, Liu X, Shi Q, He B, Zheng C and
Meng X: Breast cancer organoids and their applications for
precision cancer immunotherapy. World J Surg Oncol. 21:3432023.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ma X, Wang Q, Li G, Li H, Xu S and Pang D:
Cancer organoids: A platform in basic and translational research.
Genes Dis. 11:614–632. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yin S, Xi R, Wu A, Wang S, Li Y, Wang C,
Tang L, Xia Y, Yang D, Li J, et al: Patient-derived tumor-like cell
clusters for drug testing in cancer therapy. Sci Transl Med.
12:eaaz17232020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lancaster MA and Knoblich JA:
Organogenesis in a dish: Modeling development and disease using
organoid technologies. Science. 345:12471252014. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Drost J and Clevers H: Organoids in cancer
research. Nat Rev Cancer. 18:407–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Huch M, Gehart H, van Boxtel R, Hamer K,
Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt
J, et al: Long-term culture of genome-stable bipotent stem cells
from adult human liver. Cell. 160:299–312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gjorevski N, Sachs N, Manfrin A, Giger S,
Bragina ME, Ordóñez-Morán P, Clevers H and Lutolf MP: Designer
matrices for intestinal stem cell and organoid culture. Nature.
539:560–564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Fatehullah A, Tan SH and Barker N:
Organoids as an in vitro model of human development and disease.
Nat Cell Biol. 18:246–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Neal JT, Li X, Zhu J, Giangarra V,
Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et
al: Organoid modeling of the tumor immune microenvironment. Cell.
175:1972–1988.e16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Szymański P, Markowicz M and
Mikiciuk-Olasik E: Adaptation of high-throughput screening in drug
discovery-toxicological screening tests. Int J Mol Sci. 13:427–452.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sun A, Moore TW, Gunther JR, Kim MS,
Rhoden E, Du Y, Fu H, Snyder JP and Katzenellenbogen JA:
Discovering small-molecule estrogen receptor α/coactivator binding
inhibitors: High-throughput screening, ligand development, and
models for enhanced potency. ChemMedChem. 6:654–666. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gligorich KM, Vaden RM, Shelton DN, Wang
G, Matsen CB, Looper RE, Sigman MS and Welm BE: Development of a
screen to identify selective small molecules active against
patient-derived metastatic and chemoresistant breast cancer cells.
Breast Cancer Res. 15:R582013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
He C, Han S, Chang Y, Wu M, Zhao Y, Chen C
and Chu X: CRISPR screen in cancer: Status quo and future
perspectives. Am J Cancer Res. 11:1031–1050. 2021.PubMed/NCBI
|
|
119
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan
T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Tuijnenburg P, Aan de Kerk DJ, Jansen MH,
Morris B, Lieftink C, Beijersbergen RL, van Leeuwen EMM and
Kuijpers TW: High-throughput compound screen reveals mTOR
inhibitors as potential therapeutics to reduce (auto)antibody
production by human plasma cells. Eur J Immunol. 50:73–85. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yu K, Toral-Barza L, Shi C, Zhang WG,
Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al:
Biochemical, cellular, and in vivo activity of novel
ATP-competitive and selective inhibitors of the mammalian target of
rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
André F, Ciruelos E, Rubovszky G, Campone
M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al:
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced
breast cancer. N Engl J Med. 380:1929–1940. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Turner NC, Oliveira M, Howell SJ, Dalenc
F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl
S, et al: Capivasertib in hormone receptor-positive advanced breast
cancer. N Engl J Med. 388:2058–2070. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang J, Gong GQ, Zhou Y, Lee WJ, Buchanan
CM, Denny WA, Rewcastle GW, Kendall JD, Dickson JMJ, Flanagan JU,
et al: High-throughput screening campaigns against a PI3Kα isoform
bearing the H1047R mutation identified potential inhibitors with
novel scaffolds. Acta Pharmacol Sin. 39:1816–1822. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Miller TW, Balko JM and Arteaga CL:
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast
cancer. J Clin Oncol. 29:4452–4461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Stemke-Hale K, Gonzalez-Angulo AM, Lluch
A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et
al: An integrative genomic and proteomic analysis of PIK3CA, PTEN,
and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Razavi P, Chang MT, Xu G, Bandlamudi C,
Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, et
al: The genomic landscape of endocrine-resistant advanced breast
cancers. Nat Genet. 50:1426–1431. 2018.PubMed/NCBI
|
|
130
|
Kwon KK, Lee J, Kim H, Lee DH and Lee SG:
Advancing high-throughput screening systems for synthetic biology
and biofoundry. Curr Opin Systems Biol. 37:1004872024. View Article : Google Scholar
|
|
131
|
De Stefano P, Bianchi E and Dubini G: The
impact of microfluidics in high-throughput drug-screening
applications. Biomicrofluidics. 16:0315012022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Serrano DR, Luciano FC, Anaya BJ, Ongoren
B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA,
Tomietto G, et al: Artificial intelligence (AI) applications in
drug discovery and drug delivery: Revolutionizing personalized
medicine. Pharmaceutics. 16:13282024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Alakwaa FM, Chaudhary K and Garmire LX:
Deep learning accurately predicts estrogen receptor status in
breast cancer metabolomics data. J Proteome Res. 17:337–347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi
J, Zhou YF, Fu T, Lin CJ, Dai LJ, et al: Integrated multiomic
profiling of breast cancer in the Chinese population reveals
patient stratification and therapeutic vulnerabilities. Nat Cancer.
5:673–690. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhang H, Yang F, Xu Y, Zhao S, Jiang YZ,
Shao ZM and Xiao Y: Multimodal integration using a machine learning
approach facilitates risk stratification in HR+/HER2-breast cancer.
Cell Rep Med. 6:1019242025. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Turnbull AK, Arthur LM, Renshaw L,
Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH and
Dixon JM: Accurate prediction and validation of response to
endocrine therapy in breast cancer. J Clin Oncol. 33:2270–2278.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sgroi DC, Treuner K, Zhang Y, Piper T,
Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, et
al: Correlative studies of the breast cancer index (HOXB13/IL17BR)
and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended
endocrine therapy benefit: A Trans-aTTom study. Breast Cancer Res.
24:902022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Mosly D, Turnbull A, Sims A, Ward C and
Langdon S: Predictive markers of endocrine response in breast
cancer. World J Exp Med. 8:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Sammut SJ, Crispin-Ortuzar M, Chin SF,
Provenzano E, Bardwell HA, Ma W, Cope W, Dariush A, Dawson SJ,
Abraham JE, et al: Multi-omic machine learning predictor of breast
cancer therapy response. Nature. 601:623–629. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wu X, Li Y, Chen J, Chen J, Zhang W, Lu X,
Zhong X, Zhu M, Yi Y and Bu H: Multimodal recurrence risk
prediction model for HR+/HER2-early breast cancer following
adjuvant chemo-endocrine therapy: Integrating pathology image and
clinicalpathological features. Breast Cancer Res. 27:272025.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Gu JY, Zhang JF, Zeng SL, Zhang WY, Xia
RP, Wang XX, Zhou Q, Guo SX, Wang HZ and Chen ZS: Artificial
intelligence in tumor drug resistance: Mechanisms and treatment
prospects. Intelligent Oncol. 1:73–88. 2025. View Article : Google Scholar
|
|
142
|
Mao Y, Shangguan D, Huang Q, Xiao L, Cao
D, Zhou H and Wang YK: Emerging artificial intelligence-driven
precision therapies in tumor drug resistance: Recent advances,
opportunities, and challenges. Mol Cancer. 24:1232025. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Saha S, Mahapatra S, Khanra S, Mishra B,
Swain B, Malhotra D, Saha S, Panda VK, Kumari K, Jena S, et al:
Decoding breast cancer treatment resistance through genetic,
epigenetic, and immune-regulatory mechanisms: From molecular
insights to translational perspectives. Cancer Drug Resist.
8:362025.PubMed/NCBI
|
|
144
|
Eckardt JN, Wendt K, Bornhäuser M and
Middeke JM: Reinforcement learning for precision oncology. Cancers
(Basel). 13:46242021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Jayaraman P, Desman J, Sabounchi M,
Nadkarni GN and Sakhuja A: A primer on reinforcement learning in
medicine for clinicians. NPJ Digit Med. 7:3372024. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Bozcuk HŞ and Artaç M: A simulated trial
with reinforcement learning for the efficacy of Irinotecan and
Ifosfamide versus Topotecan in relapsed, extensive stage small cell
lung cancer. BMC Cancer. 24:12072024. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Lu Y, Chu Q, Li Z, Wang M, Gatenby R and
Zhang Q: Deep reinforcement learning identifies personalized
intermittent androgen deprivation therapy for prostate cancer.
Brief Bioinform. 25:bbae0712024. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhao M, Hanson KA, Zhang Y, Zhou A and
Cha-Silva AS: Place in therapy of Cyclin-dependent Kinase 4/6
inhibitors in breast cancer: A targeted literature review. Target
Oncol. 18:327–358. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Kappel C, Elliott MJ, Kumar V, Nadler MB,
Desnoyers A and Amir E: Comparative overall survival of CDK4/6
inhibitors in combination with endocrine therapy in advanced breast
cancer. Sci Rep. 14:31292024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Rudin C: Stop explaining black box machine
learning models for high stakes decisions and use interpretable
models instead. Nat Mach Intell. 1:206–215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Topol EJ: High-performance medicine: The
convergence of human and artificial intelligence. Nat Med.
25:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lundberg SM and Lee SI: A unified approach
to interpreting model predictions. Adv Neural Inf Process Syst.
30:4768–4777. 2017.PubMed/NCBI
|
|
153
|
Beam AL and Kohane IS: Big data and
machine learning in health care. JAMA. 319:1317–1318. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Collins GS, Reitsma JB, Altman DG and
Moons KG: Transparent reporting of a multivariable prediction model
for individual prognosis or diagnosis (TRIPOD): The TRIPOD
statement. BMJ. 350:g75942015. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Liu X, Cruz Rivera S, Moher D, Calvert MJ
and Denniston AK; SPIRIT-AI; CONSORT-AI Working Group, : Reporting
guidelines for clinical trial reports for interventions involving
artificial intelligence: The CONSORT-AI extension. Lancet Digit
Health. 2:e537–e548. 2020. View Article : Google Scholar : PubMed/NCBI
|
